<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Filon MJ</submitter><funding>University of Wisconsin Carbone Cancer Center</funding><funding>U.S. Department of Defense</funding><funding>NIH Clinical Center</funding><funding>NCI NIH HHS</funding><funding>American Urological Association Foundation</funding><pagination>1547-1557</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9804183</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>82(16)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Androgen deprivation therapy (ADT) has been the standard of care for advanced hormone-sensitive prostate cancer (PC), yet tumors invariably develop resistance resulting in castrate-resistant PC. The acute response of cancer cells to ADT includes apoptosis and cell death, but a large fraction remains arrested but viable. In this study, we focused on intensively characterizing the early metabolic changes that result after ADT to define potential metabolic targets for treatment.&lt;h4>Methods&lt;/h4>A combination of mass spectrometry, optical metabolic imaging which noninvasively measures drug responses in cells, oxygen consumption rate, and protein expression analysis was used to characterize and block metabolic pathways over several days in multiple PC cell lines with variable </pubmed_abstract><journal>The Prostate</journal><pubmed_title>Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.</pubmed_title><pmcid>PMC9804183</pmcid><funding_grant_id>R01 CA185747</funding_grant_id><funding_grant_id>R37 CA22</funding_grant_id><funding_grant_id>PCRP 150221</funding_grant_id><funding_grant_id>Tariq Khemees</funding_grant_id><funding_grant_id>R01 CA211082</funding_grant_id><funding_grant_id>P30 CA014520</funding_grant_id><funding_grant_id>R01 CA205101</funding_grant_id><pubmed_authors>Khemees TA</pubmed_authors><pubmed_authors>Skala MC</pubmed_authors><pubmed_authors>Jarrard DF</pubmed_authors><pubmed_authors>Yang B</pubmed_authors><pubmed_authors>Gillette AA</pubmed_authors><pubmed_authors>Filon MJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.</name><description>&lt;h4>Background&lt;/h4>Androgen deprivation therapy (ADT) has been the standard of care for advanced hormone-sensitive prostate cancer (PC), yet tumors invariably develop resistance resulting in castrate-resistant PC. The acute response of cancer cells to ADT includes apoptosis and cell death, but a large fraction remains arrested but viable. In this study, we focused on intensively characterizing the early metabolic changes that result after ADT to define potential metabolic targets for treatment.&lt;h4>Methods&lt;/h4>A combination of mass spectrometry, optical metabolic imaging which noninvasively measures drug responses in cells, oxygen consumption rate, and protein expression analysis was used to characterize and block metabolic pathways over several days in multiple PC cell lines with variable </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2025-04-05T12:10:17.754Z</modification><creation>2025-04-05T12:10:17.754Z</creation></dates><accession>S-EPMC9804183</accession><cross_references><pubmed>35980831</pubmed><doi>10.1002/pros.24428</doi></cross_references></HashMap>